(WGS) GeneDx Holdings - Overview
Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NASDAQ (USA) | Market Cap: 1.574m USD | Total Return: -24.5% in 12m
Avg Turnover: 59.7M
Qual. Beats: 0
Rev. Trend: 95.9%
Qual. Beats: -1
Warnings
Interest Coverage Ratio -28.6 is critical
Altman Z'' -6.88 < 1.0 - financial distress zone
Tailwinds
No distinct edge detected
GeneDx Holdings Corp. (WGS) is a Connecticut-based genomics firm specializing in pediatric and rare disease diagnostics. The company utilizes whole exome and genome sequencing to provide clinical insights, supported by an AI-driven platform designed for the analysis and interpretation of complex genetic data across hereditary risk and oncology sectors.
The business model relies on high-complexity laboratory testing services where proprietary datasets enhance the accuracy of variant interpretation. In the precision medicine sector, whole genome sequencing is increasingly favored over targeted panels due to its ability to identify diagnostic answers for previously undiagnosed conditions in a single test cycle.
For a deeper look into the companys valuation metrics and historical performance, consider reviewing the detailed analytics available on ValueRay.
Founded in 2000, GeneDx operates within the healthcare equipment and services industry, focusing on the integration of next-generation sequencing (NGS) into standard clinical workflows for rare disease management.
- Whole exome and genome sequencing adoption accelerates revenue growth in pediatrics
- Strategic shift toward high-margin diagnostic tests improves path to profitability
- AI-driven platform efficiency reduces clinical reporting costs and improves gross margins
- Expansion of commercial payer coverage increases reimbursement rates for rare disease testing
- Regulatory changes to laboratory developed tests impact genetic testing market compliance costs
| Net Income: -77.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.06 > 0.02 and ΔFCF/TA -2.73 > 1.0 |
| NWC/Revenue: 41.34% < 20% (prev 47.34%; Δ -6.00% < -1%) |
| CFO/TA -0.02 > 3% & CFO -9.31m > Net Income -77.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (29.3m) vs 12m ago 4.22% < -2% |
| Gross Margin: 68.35% > 18% (prev 65.26%; Δ 3.09% > 0.5%) |
| Asset Turnover: 92.93% > 50% (prev 73.95%; Δ 18.98% > 0%) |
| Interest Coverage Ratio: -28.62 > 6 (EBIT TTM -74.9m / Interest Expense TTM 2.62m) |
| A: 0.36 (Total Current Assets 270.6m - Total Current Liabilities 87.6m) / Total Assets 506.3m |
| B: -2.84 (Retained Earnings -1.44b / Total Assets 506.3m) |
| C: -0.16 (EBIT TTM -74.9m / Avg Total Assets 476.4m) |
| D: 1.01 (Book Value of Equity 254.1m / Total Liabilities 252.2m) |
| Altman-Z'' = -6.88 = D |
| DSRI: 1.25 (Receivables 76.9m/46.1m, Revenue 442.7m/330.1m) |
| GMI: 0.95 (GM 65.26% / 68.35%) |
| AQI: 0.83 (AQ_t 0.30 / AQ_t-1 0.36) |
| SGI: 1.34 (Revenue 442.7m / 330.1m) |
| TATA: -0.14 (NI -77.8m - CFO -9.31m) / TA 506.3m) |
| Beneish M = -2.73 (Cap -4..+1) = A |
As of June 07, 2026, the stock is trading at USD 52.21 with a total of 1,179,932 shares traded.
Over the past week, the price has changed by +0.42%,
over one month by +51.29%,
over three months by -36.33% and
over the past year by -24.52%.
GeneDx Holdings has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy WGS.
- StrongBuy: 5
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 77 | 47.5% |
P/E Forward = 166.6667
P/S = 3.5558
P/B = 6.0749
Revenue TTM = 442.7m USD
EBIT TTM = -74.9m USD
EBITDA TTM = -48.5m USD
Long Term Debt = 96.7m USD (from longTermDebt, last quarter)
Short Term Debt = 5.13m USD (from shortTermDebt, last quarter)
Debt = 239.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 71.5m
Net Debt = 69.0m USD (calculated: Debt 239.7m - CCE 170.7m)
Enterprise Value = 1.64b USD (1.57b + Debt 239.7m - CCE 170.7m)
Interest Coverage Ratio = -28.62 (Ebit TTM -74.9m / Interest Expense TTM 2.62m)
EV/FCF = -57.34x (Enterprise Value 1.64b / FCF TTM -28.7m)
FCF Yield = -1.74% (FCF TTM -28.7m / Enterprise Value 1.64b)
FCF Margin = -6.47% (FCF TTM -28.7m / Revenue TTM 442.7m)
Net Margin = -17.58% (Net Income TTM -77.8m / Revenue TTM 442.7m)
Gross Margin = 68.35% ((Revenue TTM 442.7m - Cost of Revenue TTM 140.1m) / Revenue TTM)
Gross Margin QoQ = 66.71% (prev 65.23%)
Tobins Q-Ratio = 3.25 (Enterprise Value 1.64b / Total Assets 506.3m)
Interest Expense / Debt = 1.09% (Interest Expense 2.62m / Debt 239.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -59.1m (EBIT -74.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.09 (Total Current Assets 270.6m / Total Current Liabilities 87.6m)
Debt / Equity = 0.94 (Debt 239.7m / totalStockholderEquity, last quarter 254.1m)
Debt / EBITDA = -1.42 (negative EBITDA) (Net Debt 69.0m / EBITDA -48.5m)
Debt / FCF = -2.41 (negative FCF - burning cash) (Net Debt 69.0m / FCF TTM -28.7m)
Total Stockholder Equity = 282.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -16.33% (Net Income -77.8m / Total Assets 506.3m)
RoE = -27.50% (Net Income TTM -77.8m / Total Stockholder Equity 282.9m)
RoCE = -19.72% (EBIT -74.9m / Capital Employed (Equity 282.9m + L.T.Debt 96.7m))
RoIC = -14.72% (negative operating profit) (NOPAT -59.1m / Invested Capital 401.7m)
WACC = 8.87% (E(1.57b)/V(1.81b) * Re(10.09%) + D(239.7m)/V(1.81b) * Rd(1.09%) * (1-Tc(0.21)))
Discount Rate = 10.09% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 64.44 | Cagr: 5.55%
[DCF] Fair Price = unknown (Cash Flow -28.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.80 | # QB: 0
Revenue Correlation: 95.90 | Revenue CAGR: 35.55% | SUE: -2.02 | # QB: -1
EPS current Quarter (2026-06-30): EPS=-0.19 | Chg30d=-262.06% | Revisions=-60% | Analysts=8
EPS next Quarter (2026-09-30): EPS=0.12 | Chg30d=-67.45% | Revisions=-56% | Analysts=8
EPS current Year (2026-12-31): EPS=0.11 | Chg30d=-87.93% | Revisions=-33% | GrowthEPS=-92.1% | GrowthRev=+11.9%
EPS next Year (2027-12-31): EPS=1.23 | Chg30d=-40.14% | Revisions=-40% | GrowthEPS=+1019.3% | GrowthRev=+24.4%
[Analyst] Revisions Ratio: -60%